|Send to printer »|
5 Reasons to Use OCT in Preclinical Studies
The benefits of optical coherence tomography will open your eyes.!--h2>
Optical coherence tomography (OCT) is a noninvasive imaging technology that allows for a cross-sectional view of the retina, the retinal-vitreal interface, and anterior ocular structures at near-cellular resolution. In the clinic it is used to diagnose and follow ocular degenerative diseases, but in preclinical studies it can be used to help evaluate pharmacological or toxicological drug effects.
Below are five reasons why OCT should be considered for inclusion in a preclinical toxicology study:
In summary, OCT can be a useful technology for both ocular and systemic preclinical toxicology studies by providing an in vivo, noninvasive, near-histopathology quality ocular image with the capacity for clinically relevant longitudinal evaluations of drug- or procedural-induced ocular lesions. Its sensitivity allows it to detect small defects not always visible during a routine ophthalmic examination, and in some instances its can reduce the number of animals needed in a preclinical toxicology program.
Mark Vézina is the scientific director of the Ocular and Neuroscience Department at Charles River’s preclinical site in Montreal. Mark is an active member of the Ocular Toxicology Specialty Section of the Society of Toxicology (past president) and a regular contributor to the Ocular Research Group on Linked-In. For more information on OCT, contact Charles River ([email protected]).
© 2016 Genetic Engineering & Biotechnology News, All Rights Reserved